RESUMO
OBJECTIVE: To determine the link between heart rate variability (HRV) and short-term adverse outcomes (re-hospitalisation or death due to cardiac arrhythmia, recurrent myocardial infarction, heart failure, all-cause death) in acute myocardial infarction (AMI). STUDY DESIGN: A descriptive study. Place and Duration of the Study: Department of Cardiovascular Medicine, The First Affiliated Hospital of Anhui Medical University, China, from January 2018 to December 2021. METHODOLOGY: Clinical data of 245 patients diagnosed with AMI were retrospectively analysed. After discharge from the hospital, patients were followed for a year and categorised into two groups based on the occurrence of adverse events: the adverse event group (n=82) and the no adverse event group (n=163). Differences in clinical characteristics were compared, independent factors influencing adverse events were analysed, and diagnostic efficacy was assessed. RESULTS: Univariate analysis showed age, hyperlipidaemia, specific HRV parameters (SDNN, SDANN, RMSSD, PNN50, LF/HF), and myocardial injury markers (CK-MB, cTnI, NT-proBNP) as associated with these events (all p < 0.05). Multivariable analysis revealed decreased SDNN, decreased SDANN, increased LF/HF, and elevated levels of CK-MB, cTnI, and NT-proBNP as independent influences. Both HRV parameters and myocardial injury markers were reliable predictors on ROC curve analysis. The highest diagnostic efficacy was achieved by combining these predictors. CONCLUSION: AMI patients frequently experience short-term adverse events. Both HRV parameters and myocardial injury markers, which demonstrate significant predictive efficacy, independently influence these outcomes. KEY WORDS: Acute myocardial infarction, Coronary angiography, Heart rate variability, Myocardial injury, Risk factors.
Assuntos
Insuficiência Cardíaca , Infarto do Miocárdio , Humanos , Frequência Cardíaca/fisiologia , Estudos Retrospectivos , Infarto do Miocárdio/diagnóstico , PrognósticoRESUMO
Diabetes mellitus (DM) has been proved to be a predictor of adverse outcomes after percutaneous coronary intervention (PCI). Drug-eluting stents (DESs) could reduce the adverse events in DM patients. In this study, we aimed to analyze the clinical outcome after DES implantation in diabetic versus nondiabetic patients in China. Totally, 200 Chinese DM patients and 400 Chinese non-DM patients were enrolled in this retrospective study. Compared with non-DM patients, DM patients were more likely to have a higher incidence of cardiac death (3.5% vs. 1.0%, Pâ=â.048), stent thrombosis (2.5% vs. 0.5%, Pâ=â.044), target lesion revascularization (6.0% vs. 1.8%, Pâ=â.005), target vessel failure (15.5% vs. 8.0%, Pâ<â.001), target lesion failure (14.0% vs. 4.3%, Pâ<â.001), myocardial infarction (4.5% vs. 1.5%, Pâ=â.030), and major adverse cardiac events (12.5% vs. 5.0%, Pâ=â.001) at 2-year follow-up. However, the incidence of target vessel revascularization (7.5% vs. 5.5%, Pâ=â.340) was similar between DB and non-DB patients. Patients with DB (hazard ratio [HR]â=â2.54, Pâ=â.001), older than 80 years (HRâ=â1.33, Pâ=â.027) with hypercholesterolemia (HRâ=â1.03, Pâ<â.001), serum creatinine >177âµmol/L (HRâ=â3.04, Pâ=â.011), a history of cerebral vascular accident (HRâ=â4.29, Pâ=â.010), or a history of myocardial infarction (HRâ=â31.4, Pâ<â.001) were more likely to experience adverse events. In China, DM could also be served as an independent predictor of adverse outcomes after DES implantation. These patients should be reexamined more frequently.